SMS Pharmaceuticals gets EIR from USFDA for Kandivalasa facility

India: SMS Pharmaceuticals has announced the successful closure of inspection with the receipt of Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the inspection conducted at its API facility situated at Kandivalasa, Andhra Pradesh during the period 13th January 2020 to 17th January 2020.

This facility predominantly caters regulated markets including the USA.

SMS Pharmaceuticals Ltd is among pharmaceutical manufacturing companies in India was founded by Shri Ramesh Babu Potluri in 1990 taking over the sick facility and turning it around by changing of products within no time.

It has a wide range of process equipment fully compliant with the cGMP and WHO Standards. It is a single product manufacturing company in 1990 grew to be a multi-location group having product list spreading across an array of therapeutic segments.SMS was given the export house status in the year 1997-98.

Read also: USFDA completes inspection of Natco's Kothur formulation facility